---
marp: true
theme: default
paginate: true
footer: "PHA 548 • Benzodiazepine Sedative-Hypnotics • Medicinal Chemistry"
---

# Medicinal Chemistry of Benzodiazepine Sedative-Hypnotics

## Therapeutic Context
- Anxiety
- Insomnia (sleep onset / maintenance)
- Procedural sedation

**MedChem lens:**  
Benzodiazepines suppress CNS arousal via structure-dependent PK and metabolism.

---

## Biological Target: GABA_A Receptor
- Pentameric ligand-gated Cl⁻ channel
- Stoichiometry: 2α : 2β : 1γ
- Benzodiazepines bind the **α–γ interface**
- Positive allosteric modulators (require GABA)

---

## Benzodiazepine Pharmacophore
**5-phenyl-1,4-benzodiazepin-2-one**

Required elements:
- Aromatic ring A with C7 EWG
- Diazepine ring + C2 carbonyl
- Phenyl ring (Ring C)

Loss of these → loss of activity

---

## Key SAR Rules

| Feature | Effect |
|------|------|
| C7 EWG | ↑ affinity & potency |
| C3 –OH | ↑ polarity → Phase II clearance |
| Ortho-halogen (Ring C) | ↑ CNS penetration |
| Bulky para-substitution | ↓ or abolishes activity |
| Triazolo/imidazo fusion | ↑ potency, faster onset |

---

## Physicochemical Properties → PK

| Property | Clinical Impact |
|------|------|
| Lipophilicity | Rapid CNS entry |
| Polar –OH | Shorter duration |
| N-alkyl oxidation | Active metabolites |
| Ester “soft spot” | Ultra-short duration |

---

## Metabolism & Duration

### Long-Acting
- Diazepam
- Flurazepam
→ Active metabolites → next-day sedation

### Intermediate (3-OH)
- Temazepam
- Lorazepam
- Oxazepam
→ Glucuronidation → safer clearance

### Ultra-Short
- Remimazolam
→ Esterase hydrolysis → soft drug

---

## Therapeutic Decision Matrix

| Scenario | Structural Preference |
|------|------|
| Elderly | Avoid active metabolites |
| Liver disease | 3-OH benzodiazepines |
| Procedural sedation | Soft drug |
| Chronic insomnia | Consider non-GABA options |

---

## Common Pitfalls
- “All BZDs are interchangeable”
- “Short half-life = safe”
- “Z-drugs are not BZD-site ligands”

---

## Take-Home Message
**Structure → PK → metabolism determines safety and clinical use.**
